2025年12月34%QDII正收益 华泰柏瑞中韩半导体涨9%

Core Viewpoint - In December 2025, 34.5% of the 692 comparable QDII funds experienced a net value increase, while 453 funds saw a decline, indicating a mixed performance in the market [1]. Group 1: Fund Performance - Among the QDII funds, 239 funds had a net value increase, while 453 funds had a decrease, with 8 funds remaining flat [1]. - The top-performing funds included four from Huatai-PB, specifically the Huatai-PB Sino-Korean Semiconductor ETF and its various linked versions, with monthly gains of 8.97%, 8.63%, 8.63%, and 8.61% respectively [1]. - The Huatai-PB Sino-Korean Semiconductor ETF, established on November 2, 2022, achieved a cumulative return of 153.83% by December 31, 2025, with a net value of 2.5383 yuan [1]. Group 2: Fund Holdings and Strategies - The Huatai-PB Sino-Korean Semiconductor ETF employed a passive investment strategy closely tracking its benchmark index, achieving its investment objectives effectively [2]. - As of the end of the third quarter, the top ten holdings of the Huatai-PB Sino-Korean Semiconductor ETF included major companies such as Samsung Electronics and SK Hynix [2]. - Additionally, 35 other QDII funds recorded monthly gains between 3% and 8%, with the E Fund Global Growth Select Mixed Fund (QDII) A and C having a combined scale of 5.971 billion yuan [2]. Group 3: Underperforming Funds - In December 2025, 16 QDII funds experienced declines exceeding 10%, with three from GF Fund leading the losses [3]. - The largest fund, GF CSI Hong Kong Innovative Medicine ETF, had a scale of 24.889 billion yuan and included top holdings such as Innovent Biologics and WuXi AppTec [3]. - The fund manager, Liu Jie, has over ten years of experience managing public funds since 2014 [3].